New combo aims to tackle tough lymphoma
NCT ID NCT06252675
First seen Nov 01, 2025 · Last updated May 05, 2026 · Updated 25 times
Summary
This study tests whether combining two drugs—glofitamab and pirtobrutinib—can safely and effectively treat mantle cell lymphoma that has returned or not responded to prior therapy. About 30 adults will receive the combination. The goal is to see if the drugs work together to shrink tumors and control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, Davis
RECRUITINGDavis, California, 95616, United States
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
University of California, Los Angeles
RECRUITINGLos Angeles, California, 90095, United States
Contact
Contact Email: •••••@•••••
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94143, United States
Contact Email: •••••@•••••
Contact
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.